Molecular quantification, a new strategy for quality control of Chinese patent medicine containing animal-derived crude drug: Qi She in Jinlong capsule as an example

Li, Chan; Li, Fang; Ye, Haoting; Xie, Xuena; Liang, Yongshan; Tian, Enwei; Chao, Zhi

doi:10.1016/j.jpba.2021.114428

Cited by 6 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Jinlong capsule (JLC), an animal-derived CPM prepared using modern biochemical separation technology involving low temperature and freezing, consists of 17 amino acids and a variety of bioactive peptides ( Li et al, 2022 ), which have significant anticancer activity and improve the immune function and quality of life of patients with various cancers ( Jia et al, 2020 ; Xu et al, 2020 ).…”

Section: Chinese Patent Medicines In Primary Liver Cancermentioning

confidence: 99%

Chinese Herbal Medicine for Primary Liver Cancer Therapy: Perspectives and Challenges

Xiao

Zhu

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Primary liver cancer (PLC) is one of the most common solid malignancies. However, PLC drug development has been slow, and first-line treatments are still needed; thus, studies exploring and developing alternative strategies for effective PLC treatment are urgently needed. Chinese herbal medicine (CHM) has long been applied in the clinic due to its advantages of low toxicity and targeting of multiple factors and pathways, and it has great potential for the development of novel natural drugs against PLC.Purpose: This review aims to provide an update on the pharmacological mechanisms of Chinese patent medicines (CPMs) and the latest CHM-derived compounds for the treatment of PLC and relevant clinical evaluations.Materials and Methods: A systematic search of English literature databases, Chinese literature, the Clinical Trials Registry Platform, and the Chinese Clinical Trial Registry for studies of CHMs for PLC treatment was performed.Results: In this review, we summarize the clinical trials and mechanisms of CPMs for PLC treatment that have entered the clinic with the approval of the Chinese medicine regulatory authority. These CPMs included Huaier granules, Ganfule granules, Fufang Banmao capsules, Jinlong capsules, Brucea javanica oil emulsions, and compound kushen injections. We also summarize the latest in vivo, in vitro, and clinical studies of CHM-derived compounds against PLC: icaritin and ginsenoside Rg3. Dilemmas facing the development of CHMs, such as drug toxicity and low oral availability, and future developments are also discussed.Conclusion: This review provides a deeper the understanding of CHMs as PLC treatments and provides ideas for the development of new natural drugs against PLC.

show abstract

Section: Chinese Patent Medicines In Primary Liver Cancermentioning

confidence: 99%